Today: 29 April 2026
Browse Category

NASDAQ:SLM 9 December 2025 - 10 December 2025

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
SLM Stock Plunges Over 16% After Investor Day: New EPS Targets, Analyst Downgrades and 2026–2028 Outlook for Sallie Mae (SLM)

SLM Stock Plunges Over 16% After Investor Day: New EPS Targets, Analyst Downgrades and 2026–2028 Outlook for Sallie Mae (SLM)

SLM Corporation shares plunged 16–17% to about $25.85 on December 9 after its Investor Forum revealed sharply lower earnings guidance for 2026 and 2027. Management projected FY26 EPS of $2.63, about 23% below prior consensus, and signaled higher operating expenses tied to a strategic shift. Trading volume was several times normal. The stock now trades just above its 52-week low.
9 December 2025
·

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Cambridge, Massachusetts, April 29, 2026, 09:04 EDT Biogen Inc. cut its full-year profit outlook on Wednesday, taking some shine off a first-quarter earnings beat driven by stronger sales of its Alzheimer’s drug Leqembi and newer rare-disease medicines. The Cambridge, Massachusetts-based drugmaker now expects 2026 adjusted earnings of $14.25 to $15.25 a share, down $1 at both ends of its prior range. Biogen said the cut reflects acquired in-process research and development charges, meaning costs tied to buying or licensing drug programs that are still being developed and have not yet become commercial products. (marketscreener.com) The revision matters because Biogen is
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop